Questions Before Microneedling If You Have a Keloid History

The short answer for someone with a keloid history

If you have formed a keloid, or a parent, sibling, or child has, cosmetic microneedling is a screening decision before it is a booking decision. The FDA microneedling devices page, updated October 15, 2025, says the procedure may NOT be suitable for you if you have keloid scars, or a history of keloid scars, among findings in the treatment area. No source reviewed for this article gives a personal percentage for a new keloid after cosmetic microneedling in someone already known to form them.

The reason a clinic cannot honestly quote that percentage is in Gowda and colleagues' 2021 systematic review in the Journal of Clinical and Aesthetic Dermatology. The review covered 51 articles and 1,029 patients. Most of those studies excluded people with a personal or family history of keloidal or hypertrophic scarring tendencies, and the authors write that the general risk of severe scarring is therefore difficult to assess. A claim that trials showed no keloids is a description of who was allowed into the trials.

Public clinic pages and question-and-answer threads still split. Some call any keloid history a reason to refuse facial microneedling. Others say facial keloids are uncommon and that a shallow test on the face is reasonable. Sellers of at-home devices sometimes tell keloid-prone buyers that a shallower tool avoids the problem. Those are opinions and marketing claims. They are not a measured risk, and this article does not use them as medical evidence.

What a keloid is, and why more collagen is the wrong direction for skin that over-heals

Cosmetic microneedling uses many small needles to injure the skin on purpose so it will remodel collagen. Some motorized devices let the clinician change needle depth and speed. The FDA has legally authorized specific microneedling devices to improve the appearance of facial acne scars, facial wrinkles, and abdominal scars in patients aged 22 years or older. That authorization is a statement about those uses in the patients who were studied. It is not a finding that the same injury is suitable for skin that already scars beyond the original wound.

Over-healing is not the same problem as thin skin

A keloid is scar that keeps forming and extends past the edges of the original injury. Limandjaja and colleagues, writing in Frontiers in Cell and Developmental Biology in 2020, describe keloid disorder as heterogeneous: not every keloid looks the same, and not every person with the tendency forms one after every wound. The practical conflict with microneedling is still straightforward. The procedure is built to provoke a repair response. A keloid is repair that does not stop at the wound edge. Wanting more collagen in acne scars or wrinkles does not make extra injury a good test in skin that over-heals.

Normal healing of one cut does not retire the question. The same review, summarizing earlier inheritance work, says carriers do not always show the keloid trait and people who form keloids do not form one after every injury. A flat scar on the arm and a keloid on an earlobe can belong to the same person. The history is the raised scar, not a requirement that every wound in your life looked the same.

Why a relative's keloids belong on the intake form

Limandjaja and colleagues report that having a family member with keloids is associated with higher keloid prevalence, especially for first-degree relatives, and with a higher chance of multiple keloids and more severe ones. They cite a Chinese population study for heritability estimates of 72 percent, 41 percent, and 17 percent for first-, second-, and third-degree relatives. Heritability is the share of variation in that study population attributed to inherited factors. It is not the chance that you will form a keloid because a parent has one, and it may not travel unchanged to every ancestry. The review itself traces the pattern, as summarized from Shih and Bayat in 2010, toward autosomal dominant inheritance with incomplete penetrance and variable expression. Incomplete penetrance is why someone can carry the family pattern and still have no keloid yet.

That is the screening point. A first-degree relative with keloids is a reason to tell the clinician, even when your own scars look flat. It is not a personal probability of 72 percent, and it is not an automatic order to treat or to refuse. The FDA page names the patient's own keloid scars or history of keloid scars. The trial literature also excluded family history. Both facts belong in the same conversation, and they answer different parts of it.

Chest and earlobe patterns are not a facial safety clearance

The Frontiers review illustrates two familiar patterns: a spreading keloid on the anterior chest, and a bulging keloid of the sort often seen on the earlobe. An earlobe keloid after piercing is still a keloid history for a microneedling intake, even when the planned treatment is the face. How that earlobe scar might later be repaired is a separate decision, covered in the guide to torn earlobe repair, re-piercing, and keloid risk.

Some clinicians treat the mid-face as lower risk because they see fewer facial keloids than chest or earlobe keloids. That is a clinical impression. This article did not find a measured rate of new keloids after cosmetic microneedling by body site, and the Frontiers review does not supply one. The FDA suitability item is about keloid scars or a history of keloid scars in the treatment area. It does not create a face-versus-chest exemption, and it does not say that a lower-tension area has been shown to be safe for keloid-prone skin.

What the FDA's microneedling information actually says

The microneedling devices page is a regulator's device and patient-information page. It is not the FDA guidance titled Regulatory Considerations for Microneedling Products. The devices page points to that guidance for a different question: whether a product meets the definition of a medical device and how such devices are regulated. The keloid sentence lives on the devices page, in the patient section, not in that guidance.

The page says the FDA has legally authorized microneedling devices to improve the appearance of facial acne scars, facial wrinkles, and abdominal scars in patients aged 22 years or older, after reviewing data for a reasonable assurance of safety and effectiveness for those uses. Each device's own De Novo or 510(k) summary, and its patient labeling, state what that device was authorized to do. The page tells readers those summaries are public and tells patients to ask for the patient labeling that comes with FDA-authorized devices.

The FDA consumer update, current as of October 15, 2025, uses the word cleared for the same age group and describes the studied benefits as acne scars on the face, wrinkles around the eyes and other parts of the face and neck, and surgical scars on the abdomen. Most cleared devices, it says, are pen-shaped, motorized, and meant to penetrate skin. Clearance or authorization for those appearance uses is not the same thing as an approval to deliver a drug through the needles.

Under who may not be a candidate, the devices page says the procedure may NOT be suitable for you if you have any of a longer list of conditions. One item groups actinic keratoses, keloid scars (or a history of keloid scars), warts, and birthmarks or moles in the treatment area. The next item is separate: darker skin type, because of a risk of darkening or lightening after the procedure, with the added statement that some authorized devices were not studied in subjects with darker skin types. Keloid history and darker skin are neighboring cautions. They are not the same caution.

The page does not use the word contraindication for that list, and it does not publish a risk percentage. Calling the FDA statement a nationwide ban overstates it. Skipping it because a clinic prefers the word contraindication, or prefers not to use that word, understates it. The operational reading is narrower: if there is a keloid scar, or a history of keloid scars, in the area someone wants to treat, the FDA says the procedure may not be suitable, and the decision has to be made by a clinician who has actually assessed that history.

Home devices, added products, and cartridge reuse

• No over-the-counter medical device. The consumer update says the FDA has not authorized any microneedling medical device for over-the-counter sale. It also says a product that does not have longer or sharp needles that penetrate the skin, and that only claims to help exfoliate or improve the look of the skin, is generally not a medical device. A short, blunt roller sold only as an exfoliator is in that second group. That classification is not evidence the product is safe for someone who forms keloids, and it is not permission to use a penetrating device at home.

• Not cleared for use with another product. The consumer update says the FDA has not cleared any microneedling device for use with creams, ointments, other drugs, cosmetics, or platelet-rich plasma, and has not reviewed the safety or effectiveness of those combinations. The devices page says microneedling devices are not approved for delivery of cosmetics, topical medications, vitamin solutions, drugs, or blood products such as platelet-rich plasma into the skin. The boundary is explained further in the article on microneedling devices and PRP, drugs, or fillers.

• A new cartridge each session. The devices page says to ask whether a new microneedle cartridge is used for each patient and for each session with the same patient. Reuse is unsafe and is not consistent with FDA review and authorization, even if the cartridge is cleaned. The consumer update adds that reuse can cause or spread infection. What to ask about opening and discarding a cartridge is covered in patient questions on cartridge reuse and sterility.

The evidence gap nobody puts on the consent form

Gowda and colleagues set out to catalog adverse effects of microneedling, including standard microneedling and radiofrequency microneedling. Their abstract says the review found microneedling, regardless of the specific device, to be a relatively safe procedure with minimal adverse effects, including expected redness, pain, swelling, and temporary irritation. That sentence describes the patients in the studies. In the body of the same paper, the authors write that most studies excluded a personal or family history of keloidal or hypertrophic scarring tendencies, and thus the general risk of severe scarring is difficult to assess. Both sentences have to stay in view. Relative safety in an excluded population is not a safety result for the people who were excluded.

The review also says scarring can occur in people with no scarring-disorder history. It discusses tram-track scarring after radiofrequency microneedling. Pahwa and colleagues, as cited there, attribute tram-track scarring in their study to excessive pressure over a bony prominence. Yadav and Dogra attribute the finding to nickel-contact dermatitis from radiofrequency microneedling devices. The patients with tram-tracking had no history of scarring disorders. The review does not pick a single cause. Needle material is a separate question, discussed in microneedling and metal allergy. What the keloid-history reader should take from tram-track reports is narrower: patterned scarring has been described after microneedling even when the patient had no known scarring disorder, so absence of a keloid history is not a guarantee, and presence of one was mostly never studied.

The practical recommendation in that paper is examination, not a formula. The authors say careful examination of patients' existing scars, and a discussion of scarring potential, is encouraged. They add that providers or patients with concerns about scarring can consider a trial of microneedling in an area of skin that is less visible. They do not publish a needle depth, a patch size, a body site, or a number of weeks that turns that trial into proof of safety.

Later narrative reviews use stronger clinical wording, still without a rate. Ciozda and colleagues, in a 2025 review, list contraindications that include active acne, herpes and other infections at the treatment site, a tendency to develop keloid scars, and broken skin in the treatment area. Jaiswal and Jawade, in a 2024 Cureus review, write that persistent scarring, though uncommon, can occur, particularly if the procedure is performed incorrectly or if the patient has a history of keloid formation, and that people with a history of keloid scarring may be at increased risk of scars from the procedure. Ciozda is using the word contraindication. The FDA page is using may not be suitable. Neither paper replaces the missing trial.

What a screening conversation can decide, and what it cannot

Because the trials do not contain a calculator, the useful consult is a record of history and an examination, not a percentage. Four questions cover what the sources actually speak to: whether you have formed a keloid or a hypertrophic scar, where those scars are, whether a first-degree relative has keloids, and whether a keloid scar or that history sits in the area someone proposes to treat. The diagram below stops at those questions. It does not assign a needle depth, and it does not turn the 72 percent heritability estimate into a branch of personal risk.

flowchart TD
  A["Personal keloid history or keloids in a close relative"] --> B["Name every raised scar and where it is"]
  B --> C["Clinician examines those scars in person"]
  C --> D{"Keloid scar or keloid history in the planned treatment area?"}
  D -->|Yes| E["FDA device page: the procedure may not be suitable in that area"]
  D -->|No or unclear| F["Still no published personal risk percentage"]
  F --> G{"Do scarring concerns remain after the exam?"}
  G -->|Yes| H["JCAD review: a trial in a less visible area can be considered"]
  G -->|No| I["Judgment only. Not a trial result in keloid-formers"]
  E --> J["Neither path sets a needle depth or clears cosmetic needling"]
  H --> J
  I --> J

Gowda and colleagues encourage careful examination of existing scars. A checkbox on a form, or a video visit that never looks at the earlobe, the chest, or an old surgical scar, is not that examination. If scarring remains a concern, the same review says a trial in a less visible area can be considered. It does not say a check the next day answers the keloid question. The FDA consumer update describes ordinary microneedling skin damage, such as redness, bruising, and peeling, as something that often settles over days or weeks. A keloid is scar that grows past the original injury, which is a different finding. A next-day look cannot show that a keloid will not form later.

A less-visible trial, if a clinician offers one, is still microneedling. It uses the same kind of injury, on a smaller area, in a person the published trials mostly did not enroll. It is a way to gather information about that person's scar behavior. It is not a published protocol with a required patch size, a required depth, or a week at which a flat patch becomes clearance for the whole face.

But doesn't microneedling treat keloids? Reading those headlines correctly

Search results sometimes say microneedling treats keloids. The papers behind that sentence are not cosmetic collagen treatments, and each one is a single patient.

Karina, Ekaputri, Andrew, and Biben reported microneedle electroporation to deliver corticosteroid into an existing keloid, published in Acta Dermato-Venereologica in 2023. The Vancouver Scar Scale, which runs from 0 to 13, moved from 6 to 1. The procedure was done 15 times. The authors note a long gap when the patient was not treated, which can confound the result: about 26 months passed from the first session to the final photograph, of which about eight months were routine treatment. They describe the approach as needing clinical trials before efficacy and safety are established. The needles were a way to get triamcinolone into a scar that was already there. They were not a facial treatment for wrinkles or acne scars. The devices page says microneedling devices are not approved for delivery of drugs into the skin, so a cosmetic visit is not this protocol.

Juhasz, Fackler, Pham, and Mesinkovska reported a different single-patient case in the Journal of Clinical and Aesthetic Dermatology in 2020. The diagnosis was hypertrophic scarring, not keloid disorder, in a patient with Fitzpatrick skin type IV. Treatment combined radiofrequency microneedling with topical and intralesional corticosteroids and intralesional onabotulinumtoxinA. At three weeks, the authors describe improvement in color and texture, and the patient reported no side effects. They contrast radiofrequency microneedling with fractionated lasers because laser injury at the surface might change pigment in darker skin, and they say larger studies are still needed for long-term results and adverse events. A pigment rationale in one hypertrophic-scar case is not evidence that radiofrequency microneedling is safe in people who form keloids.

Those two papers and a cosmetic microneedling visit differ in the patient, the target, and the drugs. Treating an existing keloid under medical supervision, needling skin that is not a keloid in someone who forms keloids, and puncturing a keloid at home are three decisions. The case reports speak only to the first, and only as early, uncontrolled experience. They do not license the second or the third.

Darker skin tones: two different safety questions

Marketing often collapses two questions into one sentence: microneedling is safer for darker skin, therefore it is safe if you form keloids. Pigment and keloid scarring are not the same outcome.

On pigment, the FDA devices page lists darker skin type on its own as a reason the procedure may not be suitable, because skin may darken or lighten, and it says some authorized devices were not studied in subjects with darker skin types. Gowda and colleagues call postinflammatory hyperpigmentation a common concern and say it may occur after multiple microneedling sessions. They also write that radiofrequency microneedling does not typically cause hypopigmentation and may be a safer option for people with darker skin, or with a history of postinflammatory hyperpigmentation, who want microneedling. That is a cautious statement about pigment, from studies that mostly excluded keloid-prone patients. It is not a Fitzpatrick IV to VI keloid-safety result, and it is not a finding that mechanical microneedling has a measured lower rate of dark marks than lasers in those skin types. Acne-scar modality choices in darker skin, including pigment risk, are a separate comparison in acne scar treatments for skin of color.

On keloids, Limandjaja and colleagues say darker-pigmented people are at higher risk, and they report older incidence figures: in the Black and Hispanic general population, about 4.5 to 6.2 percent up to 16 percent, and in Taiwanese Chinese and Caucasian populations as low as under 1 percent. They also say those figures come largely from studies several decades old, some dating to 1931, and that they know of no newer general-population incidence numbers. The higher band is not a rate for all Asian populations, the Taiwanese Chinese figure in that review is in the low group, and none of these percentages is a personal risk after microneedling. The same review notes that melanin alone does not explain the pattern: African albino populations have been reported to have keloid prevalence similar to normally pigmented Africans. Skin color is not a keloid test.

Radiofrequency adds a third, separate record. Mechanical microneedling and radiofrequency microneedling are compared as techniques in what each method does to skin. On October 15, 2025, the FDA issued a safety communication on certain uses of radiofrequency microneedling. It says the agency is aware of reports of burns, scarring, fat loss, disfigurement, and nerve damage, and of injuries that needed surgical repair or other medical care, when these devices were used for dermatologic or aesthetic skin procedures. The communication is not a study of keloid-formers. Reported scarring is still relevant to someone whose question is scarring. A clinic that cites lower pigment change, or the Juhasz case, as proof that radiofrequency is safe for keloid-prone skin is answering a different question. The communication is discussed for patients in what the FDA radiofrequency microneedling warning changes.

Questions to bring to the consultation

If you still want to discuss microneedling, the visit should establish history, look at scars, and name the device. The answers in the middle column stay inside the FDA pages and the reviews above. They are not a script that makes treatment safe. The right-hand column is a claim that goes beyond those sources.

Reports of device injuries are not a personal risk estimate either. The FDA asks patients to report problems through MedWatch. A separate review of microneedling reports in the FDA database is in what 66 MAUDE reports show. That dataset does not fill the keloid-history gap, because a report is not a rate, and the trials that might have estimated a rate excluded the relevant patients.

If the answer is no: what already-covered next steps look like

If the clinician examines the scars and advises against microneedling, that advice matches the limit of the evidence better than a promise that a shallow pass will be fine. This page does not replace the advice with a depth, a peel strength, a retinoid schedule, or a home roller. Preventing a new keloid is a different task from treating one that is already there.

An existing keloid has its own treatment ladder, including injected corticosteroid, 5-fluorouracil, vascular laser, cryotherapy, and the reasons excision often fails. Those choices, and their limits, are laid out in keloid and hypertrophic scar treatment. They are medical treatments for a scar you already have. They are not a reason to add new needle injuries across keloid-prone skin for a cosmetic goal.

A package paid for before anyone examined the scars does not change the FDA suitability language or the trial exclusions. Ask the clinic, in writing, what happens to the fee if the clinician recommends against treatment. This article cannot tell you that a refund is required. It can tell you that a sales package is not a clinical clearance.

The decision this page is for is narrow. Disclose every keloid you have formed and any keloids in close relatives. Expect the scars to be examined. Ask for the device's patient labeling. Treat a less-visible trial as an option the JCAD review allows when scarring is a concern, not as a next-day proof of safety. And read a headline about microneedling treating keloids as a single-patient drug-delivery report until a controlled study says otherwise. No such study was identified in the sources reviewed here.

Sources

1. U.S. Food and Drug Administration. Microneedling Devices. Updated October 15, 2025. Accessed October 2, 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devices

2. U.S. Food and Drug Administration. Microneedling Devices: Getting to the Point on Benefits, Risks and Safety. Consumer update, content current as of October 15, 2025. Accessed October 2, 2026. https://www.fda.gov/consumers/consumer-updates/microneedling-devices-getting-point-benefits-risks-and-safety

3. U.S. Food and Drug Administration. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling. Safety communication, October 15, 2025. Accessed October 2, 2026. https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication

4. U.S. Food and Drug Administration. Regulatory Considerations for Microneedling Products. Guidance, as linked from the microneedling devices page for device-definition questions. Accessed October 2, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-microneedling-products

5. Gowda A, Healey B, Ezaldein H, Merati M. A Systematic Review Examining the Potential Adverse Effects of Microneedling. J Clin Aesthet Dermatol. 2021;14(1):45-54. Accessed October 2, 2026. https://jcadonline.com/examining-potential-adverse-effects-microneedling

6. Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. The Keloid Disorder: Heterogeneity, Histopathology, Mechanisms and Models. Front Cell Dev Biol. 2020;8:360. doi:10.3389/fcell.2020.00360. Accessed October 2, 2026. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00360/full

7. Karina K, Ekaputri K, Andrew H, Biben JA. Microneedle Electroporation for Intralesional Administration of Corticosteroid Treatment of Keloid Scar. Acta Derm Venereol. 2023;103:adv13402. doi:10.2340/actadv.v103.13402. Accessed October 2, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC10719861/

8. Juhasz M, Fackler N, Pham C, Mesinkovska NA. Combination Therapy Using Radiofrequency Microneedling and Corticosteroids for Hypertrophic Scars: A Case Report. J Clin Aesthet Dermatol. 2020;13(12):27-28. Accessed October 2, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC7819590

9. Jaiswal S, Jawade S. Microneedling in Dermatology: A Comprehensive Review of Applications, Techniques, and Outcomes. Cureus. 2024;16(9):e70033. doi:10.7759/cureus.70033. Accessed October 2, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11499218

10. Ciozda A, Firlej E, Kowalska W, Kwiatkowska M, Bartosińska J. Micro-needling: current state of knowledge and clinical applications: a review. Postepy Dermatol Alergol. 2025;42(5):439-443. doi:10.5114/ada.2025.155419. Accessed October 2, 2026. https://www.termedia.pl/Micro-needling-current-state-of-knowledge-and-clinical-applications-a-review,7,56995,1,1.html